Accueil >
Publications >
Fanconi anemia and solid malignancies in childhood: A national retrospective study

Fanconi anemia and solid malignancies in childhood: A national retrospective study

1 mars 2015Pediatric Blood & Cancer

Auteurs

Aurore Malric, Anne-Sophie Defachelles, Thierry Leblanc, Brigitte Lescoeur, Brigitte Lacour, Michel Peuchmaur, Claude-Alain Maurage, Gaëlle Pierron, Delphine Guillemot, Catherine Dubois d'Enghien, Jean Soulier, Dominique Stoppa-Lyonnet, Franck Bourdeaut

Résumé

Background

Fanconi anemia (FA) predisposes to hematologic disorders and myeloid neoplasia in childhood and to solid cancers, mainly oral carcinomas, in early adulthood. Few cases of solid cancers have been reported in childhood.

Procedures

We conducted a national retrospective study of solid tumors occurring in patients registered with or determined to have FA during childhood in France. Phenotypic features, tumor type, cancer treatment, and outcome were analyzed. Whenever available, fresh‐frozen tumors were analyzed by microarray‐based comparative genomics hybridization.

Results

We identified eight patients with FA with solid tumor from 1986 to 2012. For two patients, the diagnosis of FA was unknown at the time of cancer diagnosis. Moreover, we identified one fetus with a brain tumor. All patients showed failure to thrive and had dysmorphic features and abnormal skin pigmentation. Seven patients had BRCA2/FANCD1 mutations; five of these featured more than one malignancy and the median age at the time of cancer diagnosis was 11 months (range 0.4–3 years). Solid tumor types included five nephroblastomas, two rhabdomyosarcomas, two neuroblastomas, and three brain tumors. Two children died from the toxic effects of chemotherapy, two patients from the cancer, and one patient from secondary leukemia. Only one BRCA2 patient was alive more than 3 years after diagnosis, after tailored chemotherapy.

Conclusion

Solid tumors are rare in FA during childhood, except in patients with BRCA2/FANCD1 mutations. The proper genetic diagnosis is mandatory to tailor the treatment. Pediatr Blood Cancer 2015;62:463–470. © 2014 Wiley Periodicals, Inc.